Affiliation:
1. N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Abstract
Backgrоund. Breast cancer molecular subtypes serve as a basis for combined treatment of the disease. Some of them (e. g. triple negative subtype) are prognostically unfavorable. Recently, we’ve demonstrated role of bone marrow B-cells in breast cancer prognosis. Correlation between these parameters (molecular subtypes and bone marrow lymphocyte subpopulations) have not yet studied.Aim. To investigate prognostic role of breast cancer molecular subtypes and to see the relationships between these subtypes and subpopulational composition of bone marrow lymphocytes.Materials and methods. Detailed study of bone marrow has been performed in all 107 patients treated in breast cancer department of N.N. Blokhin National Medical Research Center of Oncology in 2013–2016 years. Distribution of patients according to molecular subtypes were as follows: Luminal A – 36 (33.6 %) pts, Luminal B HER2-negative – 38 (35.5 %), Luminal B HER2-positive – 15 (14 %), subtype with Erb-B2 hyper-expression – 5 (4.4 %), triple negative – 13 (12.1 %). Comparison of molecular subtypes with immunological parameters was done for the following bone marrow B-lymphocyte subpopulations: CD19+, CD19+CD10+, CD19+CD38+, CD19+CD5+. The following survival data were analyzed: overall survival, relapse-free survival, progression-free survival, metastasis-free survival.Results. Breast cancer molecular subtypes were not related to overall survival of patients but influenced relapse-free survival, progression-free survival and metastasis-free survival. There were no correlation between molecular subtypes and bone marrow B-lymphocyte subpopulations CD19, CD19+CD10+, CD19+CD38+. B1-lymphocytes were related to molecular subtypes, the levels of B1 cells were significantly higher in Erb-B2 subtype compared to triple-negative subtype (p = 0.039).Conclusion. Breast cancer molecular subtypes are different in prognosis – relapse-free survival, progression-free survival and metastasis-free survival. The most prognostically unfavorable is triple-negative subtype. There are some relationships of bone marrow subpopulations and molecular subtypes of breast cancer: levels of B1-cells are much higher in Erb-B2 subtype compared to triple negative subtype (p = 0.039).
Publisher
Publishing House ABV Press
Reference7 articles.
1. Pak D.D., Rasskazova E.A., Danilova G.V. Subtypes of breast cancer. Opukholi zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2012;3–4:13–8. (In Russ.). DOI: 10.17650/1994-4098-2012-0-3-4-13-18
2. Artamonova E. V., Ognerubov N.A., Tupitsyn N.N., Letyagin V.P. Breast cancer: immunological prognostic factors. Voronezh: Izd-vo Voronezhskogo gos. un-ta, 2005. 236 p. (In Russ.).
3. Novikova I.A., Shatova Yu.S., Zlatnik E.Yu. et al. Proliferative and immunological characteristics of molecular biological subtypes of breast cancer. Mezhdunarodniy zhurnal fundamentalnykh y prikladnykh issledovaniy = International Journal of Fundamental and Applied Research 2014;11(1): 116–9. (In Russ.).
4. Tupitsyn N.N., Mkrtchan V.A., Palladina A.D., Vorotnikov I.K. Bone marrow lymphocyte populations of innate immunity in breast cancer patients. Global Journal of Medical Research: F disease 2020;20(2-F):20–7. DOI: 10.34257/GJMRFVOL20IS2PG21
5. Berdova F.K., Vorotnikov I.K., Tupitsyn N.N. Bone marrow B-lymphocyte subpopulations of breast cancer patients in the prognosis of the disease. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2020;21(1):50–6. (In Russ.). DOI: 10.17650/1726-9784-2022-21-1-50-56